Beam Therapeutics Inc. (NASDAQ:BEAM) shares are up during Wednesday’s premarket session following the release of promising clinical data regarding its treatment BEAM-302.



BEAM-302 is Beam’s lead genetic disease program for liver-targeting therapy for alpha-1 antitrypsin deficiency (AATD) that addresses the underlying pathophysiology of both liver and lung disease.



AATD is a hereditary disorder caused by low levels of protective AAT protein, leading to lung damage (emphysema, COPD) and liver disease.



<h2>Data Show AAT Levels Above Protective Threshold</h2>



The company announced updated safety and efficacy data from its ongoing Phase 1/2 trial of BEAM-302, highlighting that treatment with 60 mg of the drug led to a mean steady-state total alpha-1 antitrypsin (AAT) level of 16.1 µM.



Notably, all patients remained consistently and durably above the 11 µM protective AAT threshold, with a significant reduction in mutant Z-AAT levels.



Additionally, the trial demonstrated a well-tolerated safety profile, with no serious adverse events reported.



The company plans to initiate a global pivotal cohort in the second half of 2026, further advancing its efforts in treating alpha-1 antitrypsin deficiency (AATD).



<h2>BEAM-302 Pivotal Development</h2>



Based on feedback from the U.S. Food and Drug Administration (FDA), Beam intends to pursue an accelerated approval pathway for BEAM-302 based on a primary endpoint of AAT biomarkers evaluated over 12 months, with 60 mg as the selected dose.



To support a future biologics licensing application (BLA) submission, the company anticipates enrolling approximately 50 additional patients with AATD-associated lung disease, with or without liver disease, in an expansion of the ongoing open-label Phase 1/2 trial.



Beam expects to initiate the pivotal cohort in the second half of 2026.



<h2>Technical Indicators Reflect Mixed Momentum</h2>



Currently, Beam Therapeutics is trading 7.5% below its 20-day simple moving average (SMA) and 8.7% below its 100-day SMA, indicating some short-term weakness.



Over the past 12 months, shares have increased by 3.14% and are currently positioned closer to their 52-week highs than lows.



The RSI is at 38.84, which is considered neutral territory, while the MACD is at -0.9269, below its signal line at -0.7546, indicating bearish pressure on the stock. The combination of neutral RSI and bearish MACD suggests mixed momentum.



<ul>
<li>Key Resistance: $29.00</li>



<li>Key Support: $23.50</li>
</ul>



Analyst Consensus &amp; Recent Actions: The stock carries a Buy Rating with an average price target of $47.57. Recent analyst moves include:



<ul>
<li>RBC Capital: Sector Perform (Raises Target to $26.00) (Feb. 25)</li>



<li>Wedbush: Outperform (Raises Target to $65.00) (Feb. 25)</li>



<li>Canaccord Genuity: Initiated with Buy (Target $74.00) (Feb. 20)</li>
</ul>



Top ETF Exposure



<ul>
<li>ARK Innovation ETF (NYSE:ARKK): 3.60% Weight</li>



<li>ARK Genomic Revolution ETF (BATS:ARKG): 4.96% Weight</li>
</ul>



BEAM Stock Price Activity: Beam Therapeutics shares were up 2.71% at $24.60 during premarket trading on Wednesday, according to Benzinga Pro data.



Image via Shutterstock

LABU

SBIO

IBBQ

BEAM

Beam Therapeutics shares rose after promising clinical data from the BEAM-302 trial showed sustained alpha-1 antitrypsin (AAT) levels above the protective threshold, supporting plans for an accelerated FDA approval pathway. The trial demonstrated a well-tolerated safety profile, with no serious adverse events. The company plans to initiate a pivotal cohort in the second half of 2026, aiming to enroll 50 additional patients. Despite a recent rise, technical indicators show mixed momentum, with the stock currently trading below its moving averages. Analysts maintain a Buy rating with a target price averaging $47.57.

benzinga_article

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

ALPS Medical Breakthrough

Invesco Nasdaq Biotechnology ETF

Invesco Biotechnology & Genome ETF

Beam Therapeutics

Beam Therapeutics Gains On Clinical Update As Gene Therapy Hits Protective Protein Levels